Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes

Do glucagon-like peptide–1 receptor agonists (liraglutide) reduce stroke recurrence in patients with type 2 diabetes who have minor acute ischemic stroke or high-risk transient ischemic attack?In this randomized clinical trial of 636 participants with type 2 diabetes, 25 patients (7.9%) who were randomly assigned to receive standard therapy plus liraglutide and 44 (13.8%) of those who received standard therapy had recurrent stroke at 90 days.The results of this randomized clinical trial suggest that, compared with standard therapy, liraglutide might reduce recurrent stroke in patients with type 2 diabetes who had minor acute ischemic stroke or high-risk transient ischemic attack.

Corresponding Authors: Anding Xu, MD, Department of Neurology, the First Affiliated Hospital of Jinan University; 613 Huangpu Ave W, Tianhe District, Guangzhou 510630, China (tlil@jnu.edu.cn); Yongjun Wang, MD, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; No. 119 S Fourth Ring West Rd, Fengtai District, Beijing 100070, China (yongjunwang@ncrcnd.org.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.